Adherence to long-term use of renin-angiotensin II-aldosterone system inhibitors in children with chronic kidney disease

Table 1 Patient characteristics grouped by PDC

	Overall (n = 1271)		PDC < 80 (n = 1056)		PDC ≥ 80 (n = 215)		P value
Age at RASI index date, mean (SD), year	14.39 (4.86)		14.40 (4.79)		14.35 (5.19)		0.513
< 4	58	4.56	45	4.26	13	6.05
5–8	148	11.64	120	11.36	28	13.02
9–12	209	16.44	180	17.05	29	13.49
13–17	522	41.07	431	40.81	91	42.33
≥ 18	334	26.28	280	26.52	54	25.12
Sex, n, %							0.003
Female	621	48.86	496	46.97	125	58.14
Male	650	51.14	560	53.03	90	41.86
CKD diagnosis, n, %
CAKUT	114	8.97	95	9.00	19	8.84	0.941
Glomerular diagnosis	859	67.58	699	66.19	160	74.42	0.020
Diabetes/hypertension/gout- related nephropathy	17	1.34	14	1.33	3	1.40	1.000
Nephrotic syndrome	310	24.39	275	26.04	35	16.28	0.002
Glomerulonephritis	301	23.68	267	25.28	34	15.81	0.003
Systemic lupus erythematous	308	24.23	206	19.51	102	47.44	<.0001
Others	488	38.39	430	40.72	58	26.98	<.0001
Nephritis	134	10.54	115	10.89	19	8.84	0.464
Bartter syndrome/Fabry disease	4	0.31	3	0.28	1	0.47	0.524
Proteinuria	191	15.03	166	15.72	25	11.63	0.143
Hematuria	148	11.64	131	12.41	17	7.91	0.062
CKD	65	5.11	57	5.40	8	3.72	0.396
miscellaneous	27	2.12	23	2.18	4	1.86	1.000
Baseline comorbid conditions, n, %
Proteinuria	1001	78.76	813	76.99	188	87.44	<.000
Anemia	202	15.89	146	13.83	56	26.05	<.000
HTN-related	1248	98.19	1040	98.48	208	96.74	0.092
Mineral bone disorders	103	8.10	83	7.86	20	9.30	0.493
Diabetes	100	7.87	86	8.14	14	6.51	0.488
Hyperlipidemia	273	21.48	219	20.74	54	25.12	0.172
Time to RASI chronic therapy, year
mean (SD)	2.67 (2.55)		2.55 (2.46)		3.26 (2.89)		<.000
median (IQR)	1.79 (0.74–3.71)		1.68 (0.72–3.54)		2.38 (1.07–4.57)

PDC proportion of days covered, CKD chronic kidney disease, CAKUT congenital anomalies of kidney and urinary tract, HTN hypertension, RASI renin-angiotensin II-aldosterone system inhibitor, IQR interquartile range (25th- 75th percentile)

ISSN: 1471-2431